



Medtronic CardioVascular
8200 Coral Sea St NE
Mounds View, MN 55112
www.medtronic.com
Tel: 1 (800) 328-2518

April 9, 2009

Dear Doctor:

Medtronic Completes Acquisition of CoreValve

We are pleased to share details with you of an achievement that further expands Medtronic's comprehensive cardiovascular portfolio. Today we completed our acquisition of CoreValve Inc., developer of the ReValving[®] System for transfemoral aortic valve replacement.

CoreValve's technology was the first percutaneous aortic valve replacement system to receive European regulatory clearance and, with this acquisition, Medtronic becomes a market leader for transfemoral aortic valve procedures. Medtronic also recently acquired Ventr Technologies, Ltd., developer of the minimally-invasive, transapical Embracer[™] aortic valve replacement system currently under clinical investigation in Europe.

We believe that by offering complementary catheter-based systems, transfemoral and transapical, we will be best positioned to provide you with the tools necessary to address the individual needs of patients with aortic stenosis and who are at either high or prohibitive risk for surgery.

Medtronic will accelerate the use of these life-saving technologies through our strengths in research and development, manufacturing, quality systems and clinical education. These acquisitions will also provide opportunities for collaboration with cardiac surgeons and interventional cardiologists on the development of reliable and effective percutaneous valve therapies.

As we pass necessary clinical and regulatory milestones, we look forward to demonstrating to you the tremendous promise we believe our catheter-based aortic valve replacement platforms have for your practice and your patients. Should you have any questions today, please don't hesitate to contact me or visit www.medtronic.com/cvinnovation.

Best regards,

John Liddicoat
Vice President & General Manager
Structural Heart Disease

CAUTION: The CoreValve ReValving[®] System and the Ventr[™] Embracer System are not currently available in the USA for clinical trials or for sale.